EP08.02-135 Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)

Abstract

The EGF/EGFR pathway is involved in the emergence of resistance to MET and KRAS inhibitors. Vaccination represents an alternative to the administration of anti-EGFR monoclonal antibodies such as cetuximab or panitumumab, and we have shown that antibodies against EGF (anti-EGF VacAbs) potentiate the effects of tyrosine kinase inhibitors in vitro (TKIs). Also, a progression-free survival of 18 months was obtained in a recent Phase Ib clinical trial combining afatinib with anti-EGF VacAbs. In this study, we tested if anti-EGF VacAbs could improve the antitumor activity of capmatinib, tepotinib and sotorasib in MET amplified, MET Δ14 and KRAS mutant non-small cell lung cancer (NSCLC) cell lines.